At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 30 enrolled
Drug / intervention
Palonosetrondrug
Likely dose
Palonosetron 0.25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of Two Different Schedules of Palonosetron for the Prevention of Nausea and Vomiting in Patients With Metastatic Melanoma Receiving Concurrent Biochemotherapy
In Brief
A Phase 2 clinical trial evaluating Palonosetron for Melanoma. Completed, enrolled 30 participants across 1 site.
Detailed Summary
Primary Objectives: * Safety of palonosetron administered for control of nausea and vomiting in patients with metastatic melanoma receiving biochemotherapy. * To determine the patterns and severity of nausea and vomiting in two groups of patients with metastatic melanoma receiving biochemotherapy with palonosetron premedication using two schedules of palonosetron administration.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMelanoma
CountriesUnited States
CollaboratorsEisai Inc.
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartNov 2006
First PostedDec 2006
Primary CompletionMay 2009
TodayJul 2026
First PostedDec 18, 2006
Enrollment StartNov 1, 2006
Primary CompletionMay 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 19.5 years ago
Interventions
Palonosetrondrug
0.25 mg IV (By Vein) Daily for 2 Days or 0.25 mg IV Daily for 3 Days.